UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Market Access And Pricing Disparities of Anticancer Drugs Marketed In The Oecd Countries: Which Reality?

Value in health, 2016-05, Vol.19 (3), p.A4-A4

2016

Volltextzugriff (PDF)

PNS51 HEALTHCARE RESOURCE INDICATORS: THE WORLDWIDE TOP 3 COUNTRIES WITH THE MOST PHYSICIANS PER CAPITA VS. SAUDI ARABIA

Value in health, 2020-05, Vol.23, p.S293-S293

2020

Volltextzugriff (PDF)

ND3 ORPHAN DRUG MARKET ACCESS CHALLENGES IN EUROPEAN UNION FIVE

Value in health, 2020-05, Vol.23, p.S9-S9

2020

Volltextzugriff (PDF)

PND67 COMPARISON OF MULTIPLE SCLEROSIS DRUG PRICES IN SAUDI ARABIA VS. UNITED ARAB OF EMIRATES

Value in health, 2020-05, Vol.23, p.S271-S271

2020

Volltextzugriff (PDF)

Analysis Of Average Manufacturer Prices Of New Drugs Approved In The United States (1990-2012)

Value in health, 2014-05, Vol.17 (3), p.A18-A19

2014

Volltextzugriff (PDF)

PUK6 - Price Analysis of Immunosuppressants Which are Approved By FDA as Anti-Rejection Therapy for Kidney Transplantation in the United States

Value in health, 2018-05, Vol.21, p.S266-S266

2018

Volltextzugriff (PDF)

Price Analysis of Immunosuppressants Which are Approved By FDA as Anti-Rejection Therapy for Kidney Transplantation in the United States

Value in health, 2018-05, Vol.21, p.S266

2018

Volltextzugriff (PDF)

PCN173 - Approval of Oncology Drugs at World-Wide Level: An Independent or Linked Market?

Value in health, 2016-05, Vol.19 (3), p.A164-A164

2016

Volltextzugriff (PDF)

PCN174 - Oncology Drugs Lag Between Europe and other Countries: Comparaison between EMA and others Agencies (FDA, Health Canada, TGA, and Swissmedic)

Value in health, 2016-05, Vol.19 (3), p.A164-A165

2016

Volltextzugriff (PDF)

PND18 - Price Analysis of Multiple Sclerosis Disease-Modifying Drugs: Comparison Between Saudi Arabia and the United States

Value in health, 2016-05, Vol.19 (3), p.A62-A62

2016

Volltextzugriff (PDF)

Oncology Drugs Lag Between Europe and other Countries: Comparaison between EMA and others Agencies (FDA, Health Canada, TGA, and Swissmedic)

Value in health, 2016-05, Vol.19 (3), p.A164-A165

2016

Volltextzugriff (PDF)

Price Analysis of Multiple Sclerosis Disease-Modifying Drugs: Comparison Between Saudi Arabia and the United States

Value in health, 2016-05, Vol.19 (3), p.A62-A62

2016

Volltextzugriff (PDF)

PR1 - Market Access And Pricing Disparities of Anticancer Drugs Marketed In The Oecd Countries: Which Reality?

Value in health, 2016-05, Vol.19 (3), p.A4-A4

2016

Volltextzugriff (PDF)

Approval of Oncology Drugs at World-Wide Level: An Independent or Linked Market?

Value in health, 2020-01, Vol.19 (3), p.A164-A164

2020

Volltextzugriff (PDF)

PCN276 - Continental Comparison of Innovative Drugs Prices, The Case of Oncology Used for Treatment of Solid Tumors in Germany and The United States

Value in health, 2016-11, Vol.19 (7), p.A758-A758

2016

Volltextzugriff (PDF)

Continental Comparison of Innovative Drugs Prices, The Case of Oncology Used for Treatment of Solid Tumors in Germany and The United States

Value in health, 2016-11, Vol.19 (7), p.A758-A758

2016

Volltextzugriff (PDF)

Systematic Assessment of Decision Analytic Models for the Cost Effectiveness of Immunosuppressive Agents Used In Kidney Transplant Patients

Value in health, 2018-05, Vol.21, p.S267

2018

Volltextzugriff (PDF)

PUK11 - Systematic Assessment of Decision Analytic Models for the Cost Effectiveness of Immunosuppressive Agents Used In Kidney Transplant Patients

Value in health, 2018-05, Vol.21, p.S267-S267

2018

Volltextzugriff (PDF)

CO1 The Natural History, Clinical Outcomes and Unmet Needs of Patients with Arginase 1 Deficiency (ARG1-D): A Systematic Review of Case Reports

Value in health, 2021-06, Vol.24, p.S4-S4

2021

Volltextzugriff (PDF)

PRO37 The Epidemiology, Methods of Diagnosis, and Clinical Management of Patients with Arginase 1 Deficiency (ARG1-D): A Systematic Review

Value in health, 2021-06, Vol.24, p.S204-S204

2021

Volltextzugriff (PDF)

Overall Survival Versus Progression-Free Survival in Oncology Clinical Trials

Value in health, 2016-11, Vol.19 (7), p.A717-A717

2016

Volltextzugriff (PDF)

PCN52 - Overall Survival Versus Progression-Free Survival in Oncology Clinical Trials

Value in health, 2016-11, Vol.19 (7), p.A717-A717

2016

Volltextzugriff (PDF)

Pivotal Studies of Oncology Drugs Approved in Europe, Which Evidence Based-Medicine?

Value in health, 2016-11, Vol.19 (7), p.A717-A717

2016

Volltextzugriff (PDF)

PCN48 - Pivotal Studies of Oncology Drugs Approved in Europe, Which Evidence Based-Medicine?

Value in health, 2016-11, Vol.19 (7), p.A717-A717

2016

Volltextzugriff (PDF)

EVALUATING THE EFFICACY OF AN ARABIC METALINGUISTIC AWARENESS TRAINING PROGRAM

European Journal of Education Studies, 2023-09, Vol.10 (10)

2023

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(61)

Publikationsform

Sprache

Englisch
(75)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Market Access And Pricing Disparities of Anticancer Drugs Marketed In The Oecd Countries: Which Reality?

PNS51 HEALTHCARE RESOURCE INDICATORS: THE WORLDWIDE TOP 3 COUNTRIES WITH THE MOST PHYSICIANS PER CAPITA VS. SAUDI ARABIA

ND3 ORPHAN DRUG MARKET ACCESS CHALLENGES IN EUROPEAN UNION FIVE

PND67 COMPARISON OF MULTIPLE SCLEROSIS DRUG PRICES IN SAUDI ARABIA VS. UNITED ARAB OF EMIRATES

Analysis Of Average Manufacturer Prices Of New Drugs Approved In The United States (1990-2012)

PUK6 - Price Analysis of Immunosuppressants Which are Approved By FDA as Anti-Rejection Therapy for Kidney Transplantation in the United States

Price Analysis of Immunosuppressants Which are Approved By FDA as Anti-Rejection Therapy for Kidney Transplantation in the United States

PCN173 - Approval of Oncology Drugs at World-Wide Level: An Independent or Linked Market?

PCN174 - Oncology Drugs Lag Between Europe and other Countries: Comparaison between EMA and others Agencies (FDA, Health Canada, TGA, and Swissmedic)

PND18 - Price Analysis of Multiple Sclerosis Disease-Modifying Drugs: Comparison Between Saudi Arabia and the United States

Oncology Drugs Lag Between Europe and other Countries: Comparaison between EMA and others Agencies (FDA, Health Canada, TGA, and Swissmedic)

Price Analysis of Multiple Sclerosis Disease-Modifying Drugs: Comparison Between Saudi Arabia and the United States

PR1 - Market Access And Pricing Disparities of Anticancer Drugs Marketed In The Oecd Countries: Which Reality?

Approval of Oncology Drugs at World-Wide Level: An Independent or Linked Market?

PCN276 - Continental Comparison of Innovative Drugs Prices, The Case of Oncology Used for Treatment of Solid Tumors in Germany and The United States

Continental Comparison of Innovative Drugs Prices, The Case of Oncology Used for Treatment of Solid Tumors in Germany and The United States

Systematic Assessment of Decision Analytic Models for the Cost Effectiveness of Immunosuppressive Agents Used In Kidney Transplant Patients

PUK11 - Systematic Assessment of Decision Analytic Models for the Cost Effectiveness of Immunosuppressive Agents Used In Kidney Transplant Patients

CO1 The Natural History, Clinical Outcomes and Unmet Needs of Patients with Arginase 1 Deficiency (ARG1-D): A Systematic Review of Case Reports

PRO37 The Epidemiology, Methods of Diagnosis, and Clinical Management of Patients with Arginase 1 Deficiency (ARG1-D): A Systematic Review

Overall Survival Versus Progression-Free Survival in Oncology Clinical Trials

PCN52 - Overall Survival Versus Progression-Free Survival in Oncology Clinical Trials

Pivotal Studies of Oncology Drugs Approved in Europe, Which Evidence Based-Medicine?

PCN48 - Pivotal Studies of Oncology Drugs Approved in Europe, Which Evidence Based-Medicine?

EVALUATING THE EFFICACY OF AN ARABIC METALINGUISTIC AWARENESS TRAINING PROGRAM

Suchergebnisse filtern